Abstract:Many clinicians lack experience in managing trigeminal autonomic cephalalgias (TACs) in pregnancy and lactation. In addition to cluster headache, TACs include hemicrania continua, paroxysmal hemicrania, and short‐lasting unilateral neuralgiform headache with conjunctival injection and tearing/autonomic symptoms (SUNCT/SUNA). Treating these rare, severe headache conditions often requires off‐label drugs that have uncertain teratogenic potential. In the last few years, several new treatment options and safety do… Show more
“…These people may end up with a problematic use of opioids or illegal drugs [26]. In pregnancy and during breastfeeding, treatment with oxygen is considered safe, recommendations on use of sumatriptan are varying, from limited use to no use [45].…”
Section: Triptansmentioning
confidence: 99%
“…Repeated nerve blocks in medically refractory people with CCH led to transient attack freedom in only one third [ 75 ]. GON blocks are generally accepted for usage in pregnant and breastfeeding women [ 45 ].…”
Aim
Treatment for cluster headache is currently based on a trial-and-error approach. The available preventive treatment is unspecific and based on few and small studies not adhering to modern standards. Therefore, the authors collaborated to discuss acute and preventive treatment in cluster headache, addressing the unmet need of safe and tolerable preventive medication from the perspectives of people with cluster headache and society, headache specialist and cardiologist.
Findings
The impact of cluster headache on personal life is substantial. Mean annual direct and indirect costs of cluster headache are more than 11,000 Euros per patient. For acute treatment, the main problems are treatment response, availability, costs and, for triptans, contraindications and the maximum use allowed. Intermediate treatment with steroids and greater occipital nerve blocks are effective but cannot be used continuously. Preventive treatment is sparsely studied and overall limited by relatively low efficacy and side effects. Neurostimulation is a relevant option for treatment-refractory chronic patients. From a cardiologist’s perspective use of verapamil and triptans may be worrisome and regular follow-up is essential when using verapamil and lithium.
Conclusion
We find that there is a great and unmet need to pursue novel and targeted preventive modalities to suppress the horrific pain attacks for people with cluster headache.
Graphical Abstract
“…These people may end up with a problematic use of opioids or illegal drugs [26]. In pregnancy and during breastfeeding, treatment with oxygen is considered safe, recommendations on use of sumatriptan are varying, from limited use to no use [45].…”
Section: Triptansmentioning
confidence: 99%
“…Repeated nerve blocks in medically refractory people with CCH led to transient attack freedom in only one third [ 75 ]. GON blocks are generally accepted for usage in pregnant and breastfeeding women [ 45 ].…”
Aim
Treatment for cluster headache is currently based on a trial-and-error approach. The available preventive treatment is unspecific and based on few and small studies not adhering to modern standards. Therefore, the authors collaborated to discuss acute and preventive treatment in cluster headache, addressing the unmet need of safe and tolerable preventive medication from the perspectives of people with cluster headache and society, headache specialist and cardiologist.
Findings
The impact of cluster headache on personal life is substantial. Mean annual direct and indirect costs of cluster headache are more than 11,000 Euros per patient. For acute treatment, the main problems are treatment response, availability, costs and, for triptans, contraindications and the maximum use allowed. Intermediate treatment with steroids and greater occipital nerve blocks are effective but cannot be used continuously. Preventive treatment is sparsely studied and overall limited by relatively low efficacy and side effects. Neurostimulation is a relevant option for treatment-refractory chronic patients. From a cardiologist’s perspective use of verapamil and triptans may be worrisome and regular follow-up is essential when using verapamil and lithium.
Conclusion
We find that there is a great and unmet need to pursue novel and targeted preventive modalities to suppress the horrific pain attacks for people with cluster headache.
Graphical Abstract
“…Epidemiological enquiry (as opposed to clinical) cannot exclude all other possible causes [ 2 ]. The second relates to diagnosis of headache reported on ≥ 15 days/month, which may include chronic migraine, chronic tension-type headache and medication-overuse headache (MOH), trigeminal autonomic cephalalgias (although these have very low probability of occurrence in samples typically of N ~ 2,000 [ 61 ]), new daily-persistent headache (also rare) and, potentially, any of a small range of other, relatively uncommon, secondary headache disorders [ 60 ]. These can be identified only by expert questioning, usually with follow-up [ 62 ].…”
In order to pursue its purpose of reducing the global burden of headache, the Global Campaign against Headache has gathered data on headache-attributed burden from countries worldwide. These data, from the individual participants in adult population-based studies and child and adolescent schools-based studies, are being collated in two databases, which will be powerful resources for research and teaching and rich information sources for health policy.Here we briefly describe the structure and content of these databases, and announce the intention to make them available in due course as a free good.
“…Она очень редко возникает во время беременности, и имеются ограниченные данные об изменении характеристики приступов во время беременности [4,40]. Около 45% женщин, страдающими кластерными ГБ, сообщают о дебюте приступов до двадцатилетнего возраста [18,19], и в этом случаезаболевание оказывает существенное влияние на планирование семьи. Было показано, что женщины с ранним дебютом кластерных ГБ имеют меньше детей, по сравнению с пациентками, успевшими стать матерями до момента клинического развития кластерной ГБ [17,19].…”
Section: результатыunclassified
“…Около 45% женщин, страдающими кластерными ГБ, сообщают о дебюте приступов до двадцатилетнего возраста [18,19], и в этом случаезаболевание оказывает существенное влияние на планирование семьи. Было показано, что женщины с ранним дебютом кластерных ГБ имеют меньше детей, по сравнению с пациентками, успевшими стать матерями до момента клинического развития кластерной ГБ [17,19]. Женщины чаще испытывают хроническую форму кластерной ГБ, чем мужчины [20].…”
Headaches are a common neurological complaint during pregnancy. Most are primary and benign but secondary headaches may also occur. In the first trimester, the complaints are mainly due to primary headaches, and in the last trimester, the proportion of secondary headaches increases. This article provides clinical characteristics of secondary headaches during pregnancy. The limited range of drugs that can be used during pregnancy, in the absence of potential adverse effects on the mother and fetus/newborn, causes certain difficulties in the management of these patients. This review will consider approaches to the treatment of headaches during pregnancy. A non-drug therapeutic strategy is preferred for the treatment of primary headaches during pregnancy. Treatment should not be delayed because uncontrolled headaches can have negative effects on both the mother and the fetus. If non-drug therapy does not lead to the expected control of headache attacks, a choice should be made regarding the use of drug therapy while weighing the benefits and risks of such a choice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.